These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer. Gardner TA; Elzey BD; Hahn NM Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254 [TBL] [Abstract][Full Text] [Related]
7. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. Di Lorenzo G; Ferro M; Buonerba C BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289 [TBL] [Abstract][Full Text] [Related]
8. Two years of Provenge. Riedmann EM Hum Vaccin Immunother; 2012 Apr; 8(4):505. PubMed ID: 22832253 [No Abstract] [Full Text] [Related]
9. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. Nabhan C N Engl J Med; 2010 Nov; 363(20):1966-7; author reply 1968. PubMed ID: 21067391 [No Abstract] [Full Text] [Related]
10. An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer. Wesley JD; Whitmore J; Trager J; Sheikh N Hum Vaccin Immunother; 2012 Apr; 8(4):520-7. PubMed ID: 22370520 [TBL] [Abstract][Full Text] [Related]
11. Managed care considerations. A new era of advanced prostate cancer management. Muller R Manag Care; 2011 Sep; 20(9 Suppl 5):5. PubMed ID: 22043721 [No Abstract] [Full Text] [Related]
12. Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer. Holko P; Kawalec P Expert Rev Anticancer Ther; 2014 Jan; 14(1):63-73. PubMed ID: 24224852 [TBL] [Abstract][Full Text] [Related]
13. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer. McKarney I Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575 [TBL] [Abstract][Full Text] [Related]
14. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Patel PH; Kockler DR Ann Pharmacother; 2008 Jan; 42(1):91-8. PubMed ID: 18094343 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for advanced prostate cancer: a novel treatment option to improve survival. Peskin SR Manag Care; 2011 Sep; 20(9 Suppl 5):3-4, 6-11. PubMed ID: 22046617 [TBL] [Abstract][Full Text] [Related]
16. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention. Jarosławski S; Toumi M BioDrugs; 2015 Oct; 29(5):301-7. PubMed ID: 26403092 [TBL] [Abstract][Full Text] [Related]
17. Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. Beer TM; Schellhammer PF; Corman JM; Glodé LM; Hall SJ; Whitmore JB; Frohlich MW; Penson DF Urology; 2013 Aug; 82(2):410-5. PubMed ID: 23896100 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T? Lü C; Williams AK; Chalasani V; Martínez CH; Chin J Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858 [TBL] [Abstract][Full Text] [Related]
19. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. Drake CG J Natl Cancer Inst; 2012 Sep; 104(18):1422; author reply 1422-3. PubMed ID: 22911668 [No Abstract] [Full Text] [Related]
20. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. Kantoff PW; Higano CS; Small EJ; Whitmore JB; Frohlich MW; Schellhammer PF J Natl Cancer Inst; 2012 Jul; 104(14):1107-9; author reply 1109-12. PubMed ID: 22825556 [No Abstract] [Full Text] [Related] [Next] [New Search]